Sugi Predict

Sugi Predict / Compounds / SCHEMBL1319912

SCHEMBL1319912

SCHEMBL1319912

CC(C)NCCNC(=O)OC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.53
▸ EPHX1 P07099 1/20 0.51
▸ MAOA P21397 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ MALT1 Q9UDY8 1/20 0.44
▸ CA1 P00915 4/20 0.44
▸ CA2 P00918 4/20 0.44
▸ CA12 O43570 3/20 0.44
▸ CA9 Q16790 3/20 0.44
▸ CA7 P43166 1/20 0.43
▸ CTSK P43235 3/20 0.41
▸ CTSS P25774 2/20 0.41
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ BCHE P06276 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13483451 0.89 TDP1 (0.64) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL15597154 0.89 MEN1 (0.60) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL3341020 0.85 TDP1 (0.67) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL9435405 0.84 KMT2A (0.58) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL26523430 0.84 MEN1 (0.50) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL18823543 0.84 MEN1 (0.50) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL28888489 0.84 KMT2A (0.58) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL20997127 0.83 MEN1 (0.46) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL3795270 0.83 MEN1 (0.53) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL12253179 0.82 MEN1 (0.47) MEN1GAAKMT2ATDP1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025068983-A1 ANALGESIC THERAPEUTICS BASED ON CONJUGATION OF BIOCOMPATIBLE POLYMERS TO ION CHANNEL MODULATORS Relevium Medical (IE) 2025-04-03 — — WO disclosed
US-20250099598-A1 Analgesic Therapeutics Based on Conjugation of Biocompatible Polymers to Ion Channel Modulators Relevium Medical (IE) 2025-03-27 — — US disclosed
US-20250002522-A1 OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2025-01-02 — — US disclosed
CN-118414345-A Oligosaccharide compounds and complexes 生物技术公司 2024-07-30 — — CN disclosed
EP-4286394-A1 OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES BioNTech SE (DE) 2023-12-06 — — EP disclosed
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ NATIONAL INSTITUTES OF HEALTH 2023-05-11 — — US disclosed
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ NATIONAL INSTITUTES OF HEALTH 2023-05-11 — — US disclosed
WO-2023067126-A1 OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES BioNTech SE (DE) 2023-04-27 — — WO disclosed
WO-2021202600-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ THE SCRIPPS RESEARCH INSTITUTE (US) 2021-10-07 — — WO disclosed
CN-108707139-B Aminopyrimidine compound and preparation method and application thereof 北京鞍石生物科技有限责任公司 2021-04-06 — — CN disclosed
US-7655808-B2 Leptomycin compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-02 — — US disclosed
EP-2066318-A2 OXINDOLE DERIVATIVES AS ANTICANCER AGENTS F. Hoffmann-Roche AG (CH) 2009-06-10 — — EP disclosed
US-20090042837-A1 LEPTOMYCIN COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2009-02-12 — — US disclosed
US-7446196-B2 Leptomycin compounds KOSAN BIOSCIENCES, INCORPORATED (US) 2008-11-04 — — US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 — — US disclosed
US-20080081810-A1 OXINDOLE DERIVATIVES CHEN LI 2008-04-03 — — US disclosed
US-20080081810-A1 OXINDOLE DERIVATIVES CHEN LI 2008-04-03 — — US disclosed
US-20080081810-A1 OXINDOLE DERIVATIVES CHEN LI 2008-04-03 — — US disclosed
WO-2008034736-A2 OXINDOLE DERIVATIVES AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-03-27 — — WO disclosed
WO-2008034736-A2 OXINDOLE DERIVATIVES AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081810-A1 OXINDOLE DERIVATIVES CCNY, CCNI, RPS4Y1 MEN1 1280/4885GAA 3371/4885KMT2A 1450/4885
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 MEN1 2152/4885GAA 3707/4885KMT2A 278/4885
US-20250002522-A1 OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES OSTC, FUT6, MAN2B2 MEN1 2389/4885GAA 40/4885KMT2A 4165/4885
US-20250099598-A1 Analgesic Therapeutics Based on Conjugation of Biocompatible Polymers to Ion Channel Modulators TRPV1, TRPV4, TRPV3 MEN1 4852/4885GAA 3030/4885KMT2A 3603/4885
US-20090042837-A1 LEPTOMYCIN COMPOUNDS TPD52L2, MRPL12, LMNB1 MEN1 61/4885GAA 3419/4885KMT2A 1943/4885
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ HAVCR2, CD44, ENGASE MEN1 4309/4885GAA 119/4885KMT2A 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.